Background: Rachel completed her PhD at the University of Sydney where she characterized mechanisms of epigenetic inheritance. Research: She joined the Burr Group as a postdoc in 2022 and is investigating epigenetic dependencies in EZH2-mutant lymphoma. She is fascinated by unravelling epigenetic mechanisms and exploring their manipulation as novel cancer therapies.

Background: Binu completed her bachelor's in Microbiology from Trichandra University in Nepal and moved to Australia and completed her master's from Charles Sturt University in 2019. Research: Binu joined Burr Lab in May 2024 and is currently working as Administration Officer and also assists in lab by doing little bit of everything.

Background: Juliana completed her master’s degree in January 2020 at the University of Melbourne, where she investigated mechanisms of resistance to EGFR inhibitors in glioblastoma. Research: She began working as research officer for A/Prof Marian Burr at Peter MacCallum Cancer Centre in May 2020, investigating epigenetic mechanisms of immune evasion in cancer, and in 2021, moved with the the Burr Lab to the Australian National University. She is currently undertaking a PhD program in cancer immunology and epigenetics in the Burr group.

Background: Erin found an interest in science at the University of Adelaide where she graduated with a Bachelor of Science with a major in Immunology. She also completed Honours exploring the control of immune cell migration into solid tumours via chemokine signalling. Research: Erin is now a PhD student in the Burr Laboratory studying the epigenetic regulators of immune evasion in lung cancer, specifically Major Histocompatibility Complexes class I and class II, and how targeting MHC in solid tumours may improve outcomes to immunotherapy.

Background: Lizzy completed her honours project in Adele Lehane's lab at the Research School of Biology at ANU in 2021, where she worked on the characterisation of the PfSulP transporter in Plasmodium falciparum. Research: Lizzy is a PhD student in the Burr Lab and is currently working on a project to develop new treatments for EZH2 mutant Diffuse Large B Cell Lymphoma by understanding the mechanisms of epigenetic dysregulation driving these malignancies. She previously worked as a Research Assistant in the Burr lab for 12 months. She has experience in CRISPR-Cas9 gene editing and a range of cell and molecular biology techniques - and is excited to keep learning new techniques throughout her PhD!

Background: Ramin completed his Master’s degree in Medical Immunology from Tehran University of Medical Sciences (TUMS), where he conducted research on natural killer (NK) cell exhaustion in patients with endometriosis. Research: He joined the Burr Laboratory as a PhD student to investigate novel immunotherapy targets for lung cancer, utilizing targeted in vivo CRISPR screening to identify potential therapeutic candidates.

Background: Mahsa began her academic journey with a Bachelor's degree in Medical Laboratory Science in Iran, where she developed a strong interest in immunology. After completing her Master’s degree in Immunology, she chose to specialise in Cancer Immunology for her PhD. Research: To further strengthen her research background, she worked as a research officer for two years in Iran before commencing her PhD at the Australian National University (ANU). Her doctoral research focuses on gene manipulation using the CRISPR gene screening technique in small cell lung carcinoma (SCLC).

Background: Callum completed his Honours degree in the Burr Lab in 2025 where he worked on a project characterising novel epigenetic regulator of small cell lung cancer. In 2026, Callum has started studying a Doctor of Medicine and Surgery (MChD) at the ANU whilst continuing to work on the project. Research: As a Research Assistant, Callum now assists Juliana with understanding the epigenetic mechanisms used by small cell lung cancer and other neuroendocrine carcinomas to develop ‘immune silent’ and aggressive phenotypes. Ultimately, his work aims to help determine how these mechanisms could be manipulated to improve the efficacy of immune-based cancer therapies.